The Innate Immune System and Inflammatory Bowel Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00516776|
Recruitment Status : Completed
First Posted : August 15, 2007
Last Update Posted : February 14, 2018
The study includes individuals with ulcerative colitis, Crohn's disease and healthy controls. The purpose of this study is to examine the innate immune system (IIS) by exposing peripheral blood monocytes to various ligands relevant for stimulation of the IIS and study the immune response. Colonic mucosal samples are examined to find gene expression patterns which may distinguish the two forms of disease from each other and from healthy controls.
The hypothesis is that the innate immune system has responses unique for the disease states, and that the diseases may be differentiated by examination of gene expression patterns in mucosal biopsies.
|Condition or disease|
|Ulcerative Colitis Crohn's Disease|
|Study Type :||Observational|
|Actual Enrollment :||400 participants|
|Official Title:||The Innate Immune System and Inflammatory Bowel Disease|
|Actual Study Start Date :||June 2007|
|Actual Primary Completion Date :||December 2017|
|Actual Study Completion Date :||December 2017|
- gene expression patterns in mucosal biopsies [ Time Frame: 2 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00516776
|Dept of Cancer Research and Molecular Medicine, NTNU|
|Trondheim, Norway, NO-7489|
|Principal Investigator:||Arne K Sandvik, MD PhD||Norwegian University of Science and Technology|